Visalytics
Visalytics
approved EB-2 (NIW)

Internal Medicine Resident

Thoracic Oncology · Austria · 2022-03-15

Processing Time
133 days
Decision Date
2022-03-15
Location
Connecticut
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to continue his research on developing state-of-the-art approaches for identifying biomarkers and therapeutic targets involved in drug resistance. The work focuses on implementing these findings into routine patient care to improve survival rates for cancer patients, specifically those with thoracic cancers like lung cancer.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The research addresses the critical need for improved cancer therapies and biomarkers for drug resistance, which has significant implications for U.S. public health.

2 Well-positioned to Advance the Endeavor Met

The petitioner's academic background, 102 citations, and funding from major organizations like the Austrian Science Fund demonstrate his capability to lead this research.

3 Waiver of Job Offer and Labor Certification Met

The urgency of improving cancer survival rates and the petitioner's unique expertise make it advantageous for the U.S. to waive the standard labor certification process.

Why This Petition Was Approved

The petition was approved based on the petitioner's Ph.D. in malignant diseases and a strong publication record of 13 peer-reviewed journal articles and 16 abstracts. His work earned 102 citations and received funding from four international organizations, including the FWF Austrian Science Fund and Boehringer Ingelheim, satisfying all three Dhanasar prongs.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Grants
Reference Letters Dependent
Original Contributions

Similar Cases

Postdoctoral Researcher

Biotechnology · Taiwan

WeGreened EB-2 (NIW) approved
Maryland 26 days 2025-06-02
The petitioner proposes to continue research in cancer biology, specifically exploring the molecular mechanisms behind tumor progression and drug resistance. This work focuses on identifying novel therapeutic targets to inform the development of advanced combination therapies and precision medicine paradigms. The intended impact is to improve patient survival rates by creating safer and more effective treatment options for cancers that have evolved resistance to conventional therapies.
View Case

Postdoctoral Researcher

Biotechnology · India

WeGreened EB-2 (NIW) approved
Missouri 49 days 2025-04-01
The petitioner proposes to identify novel therapeutic targets to improve personalized medicine and enhance treatment outcomes for cancer patients. Her work focuses on addressing drug resistance in oncology by integrating synthetic biology, protein engineering, and tumor signaling analysis to develop optimized drug delivery methods.
View Case

Research Fellow

Biotechnology · China

WeGreened EB-2 (NIW) approved
Massachusetts 312 days 2025-04-10
The petitioner proposes to continue research into uncovering the genetic mechanisms that cause resistance to cancer therapies. Using state-of-the-art screening techniques, the work aims to accelerate the development of next-generation combination therapies to overcome tumor resistance. The endeavor focuses on exploring gene targets affecting immunotherapy response and examining the molecular behavior of oncogenic proteins.
View Case

Research Fellow

Biotechnology · China

WeGreened EB-2 (NIW) approved
Massachusetts 330 days 2025-04-14
The petitioner proposes to identify molecular mechanisms underlying chemotherapeutic resistance and develop molecular diagnostics for solid tumors. This work involves investigating patient-derived organoid cultures, CRISPR engineering, and high-throughput drug testing to improve early cancer detection and patient outcomes.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Healthcare cases More cases from Austria

Case data sourced from publicly available petition decisions and case studies. Decision date: 2022-03-15.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 133 days
Criteria Met 3 / 3
Evidence Types 5

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,895
Success Rate 54.2%
Sustained 2,112
Dismissed 1,687

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Austria All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist